Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

HPV vaccines protect against cancer. Could they benefit pregnancy? (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of six check out. Three claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedIn adjusted analyses, vaccination was associated with lower odds of all adverse pregnancy outcomes, with statistically significant reductions for some outcomes including preterm birth, spontaneous preterm birth, very preterm birth, pPROM, and severe SGA.View evidenceHide evidence

As stated5% lower odds of preterm birth and spontaneous preterm birth; 15% lower odds of very preterm birth; 7% lower odds of pPROM; 8% lower odds of severe SGA

Why this verdict

The listed adjusted estimates for preterm birth, spontaneous preterm birth, very preterm birth, pPROM, and severe SGA are broadly consistent with the abstract-level profile. However, the claim says vaccination was associated with lower odds of 'all adverse pregnancy outcomes,' while the profile supports lower odds for multiple listed outcomes and does not establish lower odds for every measured outcome, such as all secondary outcomes. The pPROM estimate also has an upper confidence-limit reported as 1.00, making any blanket statement of statistically significant reductions for that endpoint more delicate at abstract depth.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)

“DESIGN: Nationwide, population based matched case-control study.”
Claim 2 of 6Not coveredA nationwide study of more than 624,000 births suggests HPV vaccination may offer benefits beyond cancer prevention, with women vaccinated before age 17 showing 10% lower odds of preterm birth and 11% lower odds of spontaneous preterm birth.View evidenceHide evidence

As stated10% lower odds of preterm birth; 11% lower odds of spontaneous preterm birth

Why this verdict

The abstract-level profile supports that this was a nationwide Swedish study of 624,713 singleton births and that quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth and spontaneous preterm birth overall. It also supports only a general statement that reductions were more pronounced among women vaccinated at younger ages. However, the abstract profile does not provide the specific 'before age 17' category or the 10% and 11% stratum-specific estimates, so the lead claim's precise age-stratified magnitudes are not verifiable at this evidence depth.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)

“DESIGN: Nationwide, population based matched case-control study.”
2

Study evidence

The authors report that the reduction in odds of adverse pregnancy outcomes associated with quadrivalent HPV vaccination before pregnancy was generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Claim 3 of 6Not coveredWomen vaccinated before age 17 had lower odds of preterm birth, spontaneous preterm birth, pPROM, and severe SGA than women vaccinated later, and earlier vaccination showed significantly lower odds for preterm birth, sPTB, and pPROM compared with later vaccination.View evidenceHide evidence

As stated10% and 11% lower odds of preterm birth and sPTB; 14% lower odds of pPROM; 9% lower odds of severe SGA

Why this verdict

The abstract-level profile supports only that risk reductions were generally more pronounced among women vaccinated at younger ages. It does not provide the 'before age 17' cutoff, stratum-specific odds ratios, confidence intervals, or formal interaction results. Therefore the specific claims about 10%, 11%, 14%, and 9% lower odds and statistically lower odds compared with later vaccination cannot be verified from the supplied abstract profile.

1

Study evidence

The authors report that the reduction in odds of adverse pregnancy outcomes associated with quadrivalent HPV vaccination before pregnancy was generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Claim 4 of 6Not coveredThe article says the findings are observational, with residual confounding still possible, and that the study could not determine whether protection came from preventing HPV infection or from reducing cervical procedures.View evidenceHide evidence

Why this verdict

The observational nature of the study and the possibility of residual confounding are supported by the abstract-level profile. However, the specific statement that the study could not determine whether protection came from preventing HPV infection or from reducing cervical procedures, as well as the quoted point about numbers needed to vaccinate, is not present in the supplied abstract profile. Those specifics are therefore not verifiable at this evidence depth.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)

“DESIGN: Nationwide, population based matched case-control study.”
2

Study evidence

The authors report that the reduction in odds of adverse pregnancy outcomes associated with quadrivalent HPV vaccination before pregnancy was generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Claim 5 of 6SupportedA recent nationwide Swedish study in BMJ found that quadrivalent HPV vaccination was associated with modestly lower odds of several adverse pregnancy outcomes, especially when given earlier in life.View evidenceHide evidence

As statedmodestly lower odds

Why this verdict

The paper profile supports that the BMJ study was a nationwide Swedish observational matched case-control study and found modestly lower adjusted odds for several adverse pregnancy outcomes after quadrivalent HPV vaccination before pregnancy. The profile also states that risk reductions were generally more pronounced among women vaccinated at younger ages, matching the story's hedged associational framing.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)

“DESIGN: Nationwide, population based matched case-control study.”
2

Study evidence

The authors report that the reduction in odds of adverse pregnancy outcomes associated with quadrivalent HPV vaccination before pregnancy was generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Claim 6 of 6SupportedThe study population included 624,713 nulliparous women aged 16-35 years who gave birth to singleton infants in Sweden between 2006 and 2023, and about 15% had received the quadrivalent HPV vaccine before pregnancy.View evidenceHide evidence

As stated624,713 women; about 15% vaccinated before pregnancy

Why this verdict

The abstract reports 624,713 singleton births among nulliparous women aged 16-35 years in Sweden between 2006 and 2023, with 92,620 women, or 14.8%, having received quadrivalent HPV vaccination before pregnancy. The claim is a descriptive population statement and is supported by the profile.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)

“DESIGN: Nationwide, population based matched case-control study.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract does not report the full covariate list, matching variables, handling of missing data, detailed outcome ascertainment, or sensitivity analyses.

    These abstract-level limitations are not included in the story's listed caveats. They matter for evaluating the robustness of adjusted observational associations, although the story does include broader cautions about observational design and residual confounding.

    From Nationwide population-based matched case-control (registry-based)

  • For pPROM, the reported confidence interval reaches 1.00, and the abstract does not provide details about multiple testing or secondary outcome handling.

    The story notes that some associations were not statistically significant, but the presented claim specifically includes pPROM among statistically significant reductions. The profile's pPROM interval of 0.87 to 1.00 makes that interpretation borderline at abstract depth, and the story presentation does not reflect this nuance.

    From Nationwide population-based matched case-control (registry-based)

6 things the story did carry across
  • The study was a nationwide, population-based matched case-control observational study in Sweden using conditional logistic regression to estimate adjusted odds ratios.
  • The study population comprised 624,713 singleton births among nulliparous women aged 16-35 years in Sweden from 2006 to 2023; 92,620 women, or 14.8%, had received quadrivalent HPV vaccination before pregnancy.
  • The primary outcomes were preterm birth, including subtypes, and spontaneous preterm birth; secondary outcomes included PROM/PPROM, SGA, stillbirth, and neonatal mortality.
  • Adjusted analyses found modestly lower odds for several outcomes: preterm birth aOR 0.95, very preterm birth aOR 0.85, spontaneous preterm birth aOR 0.95, pPROM aOR 0.93, and severe SGA aOR 0.92.
  • The paper assessed effect modification by age at HPV vaccination and the abstract reports that risk reductions were generally more pronounced among women vaccinated at younger ages.
  • Because the study is observational, residual confounding and other biases remain possible.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between quadrivalent HPV vaccination before pregnancy and risk of adverse pregnancy outcomes (primary: preterm birth and spontaneous preterm birth; secondary: PROM/PPROM, SGA, stillbirth, neonatal mortality) in a nationwide Swedish population.Nationwide population-based matched case-control (registry-based)Expand

In plain English

Nationwide, population-based matched case-control study of 624,713 singleton births (nulliparous women aged 16–35 years) in Sweden (2006–2023) estimating associations between quadrivalent HPV vaccination before pregnancy and multiple adverse pregnancy outcomes. Using conditional logistic regression with multivariable adjustment, vaccination before pregnancy was associated with modestly lower adjusted odds for several adverse outcomes (notably preterm birth, very preterm birth, spontaneous preterm birth, preterm prelabour rupture of membranes, and severe small for gestational age infant). Risk reductions were generally greater for women vaccinated at younger ages.

Key findings

  • Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm birth (<37 weeks).aOR 0.95 (95% CI 0.91 to 0.99)
  • Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of very preterm birth (28–31 weeks).aOR 0.85 (95% CI 0.75 to 0.97)
“DESIGN: Nationwide, population based matched case-control study.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2secondary dataAssess whether associations between quadrivalent HPV vaccination and adverse pregnancy outcomes differ by age at vaccination (effect modification).Interaction/stratified analysis within matched case-control (conditional logistic regression)Expand

In plain English

Within the nationwide matched case-control study of HPV vaccination before pregnancy, the authors assessed effect modification by age at vaccination using interaction/stratified analyses within the same conditional logistic regression framework. The abstract reports that risk reductions associated with quadrivalent HPV vaccination were generally more pronounced among women vaccinated at younger ages, but it does not provide stratum-specific estimates, age-category definitions, or interaction test statistics in the abstract.

Key findings

  • The authors report that the reduction in odds of adverse pregnancy outcomes associated with quadrivalent HPV vaccination before pregnancy was generally more pronounced among women vaccinated at younger ages.
“Effect modification by age at human papillomavirus vaccination was assessed.”
What this piece can’t prove
  • The abstract states that effect modification by age was assessed but does not provide methodological details (age categories, interaction tests, or stratum-specific estimates).

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 38 candidate papers

Candidate

Author response for "Sequential Intracellular Delivery of Genetic Coding Molecules Using an Acoustic Electric Microfluidic Platform"

2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.